Identification of therapeutic agents with the potential to decrease TDP-43 cytoplasmic aggregation could halt TDP-43-associated toxicity and the consequent neurodegeneration, slowing down the relentless progression of the disease observed in ALS patients. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.